Management & Regulatory

FDA Approves Keytruda for Advanced Head and Neck Cancer
Management & Regulatory FDA Approves Keytruda for Advanced Head and Neck Cancer

In a significant development for cancer treatment, Merck & Co. has received the FDA's approval for Keytruda (pembrolizumab) to be used in a new treatment regimen targeting adults with certain head and neck squamous cell carcinoma (HNSCC). This marks a critical extension of Keytruda's

How Will Moderna's mRESVIA Impact Younger Adults?
Management & Regulatory How Will Moderna's mRESVIA Impact Younger Adults?

As temperatures cool and the common cold season descends, a significant health risk may be lurking unnoticed for many younger adults. Respiratory Syncytial Virus (RSV), once considered a pediatric and elderly threat, has raised concerns for adults aged 18 to 59 with underlying health conditions.

Has the FDA Simplified Cancer Treatment with Brukinsa Tablets?
Management & Regulatory Has the FDA Simplified Cancer Treatment with Brukinsa Tablets?

Ivan Kairatov is a renowned expert in the biopharma industry, particularly in the realms of technology and innovation. His expertise in research and development has helped shape advancements in targeted cancer therapies. We discuss the recent FDA approval of the tablet formulation of Brukinsa, a

NICE Endorses GSK's Blenrep Combo for Multiple Myeloma
Management & Regulatory NICE Endorses GSK's Blenrep Combo for Multiple Myeloma

Multiple myeloma remains a formidable challenge in oncology, known for its relentless cycle of relapse and treatment resistance. This blood cancer, which originates in plasma cells within the bone marrow, continues to affect patients profoundly, with around 6,240 individuals diagnosed annually in

U.S. States Lead Charge on Genetic Privacy Laws in 2025
Management & Regulatory U.S. States Lead Charge on Genetic Privacy Laws in 2025

The realm of genetic privacy has garnered profound attention from lawmakers in the United States as they confront unfolding challenges related to genetic information security and confidentiality. This year, legislative bodies have demonstrated a proactive stance on addressing pressing issues

Will Ibtrozi Become the New Standard for ROS1-Positive NSCLC?
Management & Regulatory Will Ibtrozi Become the New Standard for ROS1-Positive NSCLC?

Imagine facing the battle against a form of lung cancer so rare that it affects only about 2% of those diagnosed with non-small cell lung cancer (NSCLC). This is the reality for those with ROS1-positive NSCLC, a disease that could soon see transformative change with the approval of Nuvation

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later